ArticleBMC cancer2025
Efficacy of brain radiotherapy combined with atezolizumab and platinum-doublet chemotherapy for advanced non-small-cell lung cancer with brain metastases: a pooled analysis.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Integrated management of immunotherapy and radiotherapy for patients with metastatic non-small cell lung cancer: a narrative review of current landscape and future directions.Translational lung cancer research · 2026Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundBrain metastases (BM) are a common complication in non-small cell lung cancer (NSCLC), associated with poor prognosis and limited survival without treatment. Previous studies have demonstrated a synergistic effect between radiotherapy (RT) and immunotherapy in NSCLC. This study aims to evaluate the efficacy of combining RT, immunotherapy, and platinum-doublet chemotherapy in NSCLC patients with BM.
methodsThis study retrospectively analyzed three open-label, randomized phase III trials (IMpower130, IMpower131, and IMpower150). NSCLC patients with BM who received RT combined with immunotherapy and platinum-doublet chemotherapy (immuno-chemoRT) were compared to those treated with immunotherapy and chemotherapy alone (immuno-chemo). Propensity score matching (PSM) was applied to minimize baseline imbalances between cohorts. The primary endpoint was overall survival (OS), with progression-free survival (PFS) as the secondary endpoint.
resultsA total of 134 patients were included in the analysis (immuno-chemoRT: n = 60; immuno-chemo: n = 74). The immuno-chemoRT cohort demonstrated improved survival compared to the immuno-chemo cohort, with a median OS of 19.2 months versus 10.6 months (HR: 0.55, 95% CI: 0.35–0.86, P = 0.008) and median PFS of 7.1 months versus 5.59 months (HR = 0.54, 95% CI: 0.37–0.78, P = 0.001). After PSM (1:1), the immuno-chemoRT group maintaining longer median OS (18.7 vs. 11.8 months; HR: 0.49, 95% CI: 0.29–0.83, P = 0.007) and PFS (7.1 vs. 5.75 months; HR: 0.54, 95% CI: 0.37–0.78, P = 0.015).
conclusionsOur analysis suggests that immuno-chemoRT prolongs the OS and PFS of NSCLC patients with BM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.